REVVITY INC

Life Sciences

Revenue for the three months ended March 30, 2025 was $340.4 million, as compared to $336.5 million for the three months ended March 31, 2024, an increase of $3.9 million, or 1%, which includes an approximate 1% decrease in revenue attributable to unfavorable changes in foreign exchange rates. The increase in our Life Sciences segment revenue during the three months ended March 30, 2025 was driven by an increase of $9.0 million in Software revenue, partially offset by a decrease of $5.2 million in Life Sciences Solutions revenue.

Segment operating income for the three months ended March 30, 2025 was $105.7 million, as compared to $101.0 million for the three months ended March 31, 2024, an increase of $4.8 million, or 5%. Segment operating margin increased 106 basis points in the three months ended March 30, 2025, as compared to the three months ended March 31, 2024, primarily due to higher sales volume and productivity, and favorable product mix.

Diagnostics

Revenue for the three months ended March 30, 2025 was $324.4 million, as compared to $313.4 million for the three months ended March 31, 2024, an increase of $11.0 million, or 3%, which includes an approximate 2% decrease in revenue attributable to unfavorable changes in foreign exchange rates. Theincrease in our Diagnostics segment revenue duringthe three months ended March 30, 2025 was driven by an increase of $8.9 million in Immunodiagnostics revenue andan increase of $2.1 million in Reproductive Health revenue.

Segment operating incomefor the three months ended March 30, 2025 was $74.0 million, as compared to $76.2 millionfor the three months ended March 31, 2024, a decrease of $2.2 million, or 3%. Segment operating margin decreased 150 basis points in the three months ended March 30, 2025, as compared to the three months ended March 31, 2024, primarily due to continued investments in new product development, digital capabilities and growth initiatives, partially offset by pricing actions and higher productivity.